Discover how the new Medicare GLP-1 Bridge program improves access to weight loss medications for millions of Americans. Learn more about eligibility and benefits.

Medicare introduces coverage for GLP-1 medications targeting obesity, enhancing access for beneficiaries to affordable treatment options.

Discover how Medicare participants can access weight loss drugs for only $50 monthly, improving healthcare accessibility before the deadline of Dec 31, 2027.

Explore key trends in telehealth diagnostics, highlighting obesity and mental health in December 2025. Understand regional shifts and claims analysis.

Discover the impact of GLP-1 medications on life insurance underwriting and health outcomes, highlighting AI's role in improving predictions and insurer operations.

CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.

Medicare faces evolving opportunities and challenges in covering weight loss drugs through legislation like the Treat and Reduce Obesity Act and federal demonstration projects. Drug adherence and cost-effectiveness remain key issues.

Celebrity health journeys reveal critical insights into obesity risks, chronic disease management, and insurance implications for older Americans.

The Treat and Reduce Obesity Act introduces expanded Medicare coverage for obesity screenings, specialists, and medications, aiming to reduce obesity-related diseases and healthcare costs among seniors.

CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.